Batokine in Central Nervous System Diseases.
Brown adipose tissue
Central nervous system diseases
FGF21
GDF15
Irisin
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
28
03
2023
accepted:
06
07
2023
medline:
27
11
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Brown adipose tissue (BAT) is a special type of fat tissue in mammals and is also a key endocrine organ in the human body. Batokine, the endocrine effector of BAT, plays a neuroprotective role and improves the prognosis by exerting anti-apoptotic and anti-inflammatory effects, as well as by improving vascular endothelial function and other mechanisms in nerve injury diseases. The present article briefly reviewed several types of batokines related to central nervous system (CNS) diseases. Following this, the potential therapeutic value and future research direction of batokines for CNS diseases were chiefly discussed from the aspects of protective mechanism and signaling pathway.
Identifiants
pubmed: 37526894
doi: 10.1007/s12035-023-03490-w
pii: 10.1007/s12035-023-03490-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7021-7031Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Betz MJ, Enerbäck S (2015) Human brown adipose tissue: what we have learned so far. Diabetes 64:2352–2360. https://doi.org/10.2337/db15-0146
doi: 10.2337/db15-0146
pubmed: 26050667
Pinckard KM, Stanford KI (2021) The heartwarming effect of brown adipose Tissue. Mol Pharmacol 102:39–50. https://doi.org/10.1124/molpharm.121.000328
doi: 10.1124/molpharm.121.000328
Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiological Reviews 84:277–359. https://doi.org/10.1152/physrev.00015.2003
doi: 10.1152/physrev.00015.2003
pubmed: 14715917
Nedergaard J, Bengtsson T, Cannon B (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol-Endocrinol Metab 293:E444–E452. https://doi.org/10.1152/ajpendo.00691.2006
doi: 10.1152/ajpendo.00691.2006
pubmed: 17473055
van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508. https://doi.org/10.1056/nejmoa0808718
doi: 10.1056/nejmoa0808718
pubmed: 19357405
Cypess AM, Lehman S, Williams G et al (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517. https://doi.org/10.1056/nejmoa0810780
doi: 10.1056/nejmoa0810780
pubmed: 19357406
pmcid: 2859951
Villarroya F, Vidal-Puig A (2013) Beyond the sympathetic tone: the new brown fat activators. Cell Metabolism 17:638–643. https://doi.org/10.1016/j.cmet.2013.02.020
doi: 10.1016/j.cmet.2013.02.020
pubmed: 23583169
Scheele C, Wolfrum C (2019) Brown adipose crosstalk in tissue plasticity and human metabolism. Endocr Rev 41:53–65. https://doi.org/10.1210/endrev/bnz007
doi: 10.1210/endrev/bnz007
pmcid: 7006230
Townsend KL, Tseng Y-H (2015) Of mice and men: novel insights regarding constitutive and recruitable brown adipocytes. Int J Obes Supp 5:S15–S20. https://doi.org/10.1038/ijosup.2015.5
doi: 10.1038/ijosup.2015.5
Nishio M, Saeki K (2020) The remaining mysteries about brown adipose tissues. Cells 9:2449. https://doi.org/10.3390/cells9112449
doi: 10.3390/cells9112449
pubmed: 33182625
pmcid: 7696203
Lehnig AC, Dewal RS, Baer LA, et al (2019) Exercise training induces depot-specific adaptations to white and brown adipose tissue. iScience 11:425–439. https://doi.org/10.1016/j.isci.2018.12.033
Cannon B, Jong JMA, Fischer AW et al (2020) Human brown adipose tissue: classical brown rather than brite/beige? Exp Physiol 105:1191–1200. https://doi.org/10.1113/ep087875
doi: 10.1113/ep087875
pubmed: 32378255
de Jong JMA, Sun W, Pires ND et al (2019) Human brown adipose tissue is phenocopied by classical brown adipose tissue in physiologically humanized mice. Nat Metab 1:830–843. https://doi.org/10.1038/s42255-019-0101-4
doi: 10.1038/s42255-019-0101-4
pubmed: 32694768
Villarroya F, Cereijo R, Villarroya J, Giralt M (2016) Brown adipose tissue as a secretory organ. Nat Rev Endocrinol 13:26–35. https://doi.org/10.1038/nrendo.2016.136
doi: 10.1038/nrendo.2016.136
pubmed: 27616452
Kita S, Maeda N, Shimomura I (2019) Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest 129:4041–4049. https://doi.org/10.1172/jci129193
doi: 10.1172/jci129193
pubmed: 31483293
pmcid: 6763291
Gavaldà-Navarro A, Villarroya J, Cereijo R et al (2021) The endocrine role of brown adipose tissue: an update on actors and actions. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-021-09640-6
Fon Tacer K, Bookout AL, Ding X et al (2010) Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050–2064. https://doi.org/10.1210/me.2010-0142
doi: 10.1210/me.2010-0142
pubmed: 20667984
pmcid: 2954642
Rydén M (2009) Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 66:2067–2073. https://doi.org/10.1007/s00018-009-0003-9
doi: 10.1007/s00018-009-0003-9
pubmed: 19277467
Xie T, Leung PS (2017) Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol-Endocrinol Metab 313:E292–E302. https://doi.org/10.1152/ajpendo.00101.2017
doi: 10.1152/ajpendo.00101.2017
pubmed: 28559437
pmcid: 5625087
Kharitonenkov A (2009) FGFs and metabolism. Curr Opin Pharmacol 9:805–810. https://doi.org/10.1016/j.coph.2009.07.001
doi: 10.1016/j.coph.2009.07.001
pubmed: 19683963
Tan BK, Hallschmid M, Adya R et al (2011) Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid. Diabetes 60:2758–2762. https://doi.org/10.2337/db11-0672
doi: 10.2337/db11-0672
pubmed: 21926274
pmcid: 3198100
Hsuchou H, Pan W, Kastin AJ (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides 28:2382–2386. https://doi.org/10.1016/j.peptides.2007.10.007
doi: 10.1016/j.peptides.2007.10.007
pubmed: 17996984
pmcid: 2151924
Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774–781. https://doi.org/10.1210/en.2006-1168
doi: 10.1210/en.2006-1168
pubmed: 17068132
Lin Z, Pan X, Wu F et al (2015) Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131:1861–1871. https://doi.org/10.1161/circulationaha.115.015308
doi: 10.1161/circulationaha.115.015308
pubmed: 25794851
pmcid: 4444420
Yan X, Chen J, Zhang C et al (2015) FGF 21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med 19:1557–1568. https://doi.org/10.1111/jcmm.12530
doi: 10.1111/jcmm.12530
pubmed: 25823710
pmcid: 4511354
Yu Y, Bai F, Wang W et al (2015) Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacol Biochem Behav 133:122–131. https://doi.org/10.1016/j.pbb.2015.03.020
doi: 10.1016/j.pbb.2015.03.020
pubmed: 25871519
Huang X, Hu J, Li Y et al (2013) The cell adhesion molecule L1 regulates the expression of FGF21 and enhances neurite outgrowth. Brain Res 1530:13–21. https://doi.org/10.1016/j.brainres.2013.07.043
doi: 10.1016/j.brainres.2013.07.043
pubmed: 23916735
Sa-nguanmoo P, Chattipakorn N, Chattipakorn SC (2016) Potential roles of fibroblast growth factor 21 in the brain. Metab Brain Dis 31:239–248. https://doi.org/10.1007/s11011-015-9789-3
doi: 10.1007/s11011-015-9789-3
pubmed: 26738728
Sideromenos S, Gundacker A, Nikou M et al (2022) Uncoupling protein-1 modulates anxiety-like behavior in a temperature-dependent manner. J Neurosci 42:7659–7672. https://doi.org/10.1523/jneurosci.2509-21.2022
doi: 10.1523/jneurosci.2509-21.2022
pubmed: 36194650
pmcid: 9546448
Yang X, Hui Q, Yu B et al (2022) Correction to “Design and evaluation of lyophilized fibroblast growth factor 21 and its protection against ischemia cerebral injury.”. Bioconjugate Chem 33:1437–1438. https://doi.org/10.1021/acs.bioconjchem.2c00234
doi: 10.1021/acs.bioconjchem.2c00234
Kuroda M, Muramatsu R, Maedera N et al (2017) Peripherally derived FGF21 promotes remyelination in the central nervous system. J Clin Invest 127:3496–3509. https://doi.org/10.1172/jci94337
doi: 10.1172/jci94337
pubmed: 28825598
pmcid: 5669554
Li S, Yu Y, Li L et al (2015) Treatment of CIA mice with FGF21 down-regulates TH17-IL-17 axis. Inflammation 39:309–319. https://doi.org/10.1007/s10753-015-0251-9
doi: 10.1007/s10753-015-0251-9
Hui X, Feng T, Liu Q et al (2016) The FGF21–adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol 8:110–119. https://doi.org/10.1093/jmcb/mjw013
doi: 10.1093/jmcb/mjw013
pubmed: 26993043
Gómez-Sámano MÁ, Grajales-Gómez M, Zuarth-Vázquez JM et al (2017) Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biology 11:335–341. https://doi.org/10.1016/j.redox.2016.12.024
doi: 10.1016/j.redox.2016.12.024
pubmed: 28039838
Wang N, Li J, Li S et al (2018) Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. Biomed Pharmacother 108:1825–1834. https://doi.org/10.1016/j.biopha.2018.09.143
doi: 10.1016/j.biopha.2018.09.143
pubmed: 30372888
Tanajak P, Chattipakorn SC, Chattipakorn N (2015) Effects of fibroblast growth factor 21 on the heart. J Endocrinol 227:R13–R30. https://doi.org/10.1530/joe-15-0289
doi: 10.1530/joe-15-0289
pubmed: 26341481
Xie Z, Dong X et al (2019) HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways. Biomolecules 9:512. https://doi.org/10.3390/biom9100512
doi: 10.3390/biom9100512
pubmed: 31547018
pmcid: 6843331
Moskowitz MA, Lo EH, Iadecola C (2010) The science of stroke: mechanisms in search of treatments. Neuron 68:161. https://doi.org/10.1016/j.neuron.2010.08.019
doi: 10.1016/j.neuron.2010.08.019
Wang D, Liu F, Zhu L et al (2020) FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. J Neuroinflammation 17(1):257. https://doi.org/10.1186/s12974-020-01921-2
doi: 10.1186/s12974-020-01921-2
pubmed: 32867781
pmcid: 7457364
Tang Y, Le W (2015) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181–1194. https://doi.org/10.1007/s12035-014-9070-5
doi: 10.1007/s12035-014-9070-5
pubmed: 25598354
Ma Y, Wang J, Wang Y, Yang G-Y (2017) The biphasic function of microglia in ischemic stroke. Prog Neurobiol 157:247–272. https://doi.org/10.1016/j.pneurobio.2016.01.005
doi: 10.1016/j.pneurobio.2016.01.005
pubmed: 26851161
Bookout AL, de Groot MHM, Owen BM et al (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147–1152. https://doi.org/10.1038/nm.3249
doi: 10.1038/nm.3249
pubmed: 23933984
pmcid: 3769420
Kurosu H, Choi M, Ogawa Y et al (2007) Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687–26695. https://doi.org/10.1074/jbc.m704165200
doi: 10.1074/jbc.m704165200
pubmed: 17623664
Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires βklotho to act in vivo. PLoS One 7:e49977. https://doi.org/10.1371/journal.pone.0049977
doi: 10.1371/journal.pone.0049977
pubmed: 23209629
pmcid: 3507945
Itoh N, Ornitz DM (2010) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:121–130. https://doi.org/10.1093/jb/mvq121
doi: 10.1093/jb/mvq121
pubmed: 20940169
pmcid: 3106964
Chen J, Hu J, Liu H et al (2018) FGF21 protects the blood–brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury. J Neurotrauma 35:2091–2103. https://doi.org/10.1089/neu.2017.5271
doi: 10.1089/neu.2017.5271
pubmed: 29648978
Jiang Y, Liu N, Wang Q et al (2018) Endocrine regulator rFGF21 (recombinant human fibroblast growth factor 21) improves neurological outcomes following focal ischemic stroke of type 2 diabetes mellitus male mice. Stroke 49:3039–3049. https://doi.org/10.1161/strokeaha.118.022119
doi: 10.1161/strokeaha.118.022119
pubmed: 30571410
pmcid: 6310061
Pan J, Jin J, Ge H et al (2015) Malibatol A regulates microglia M1/M2 polarization in experimental stroke in a PPARγ-dependent manner. J Neuroinflammation 14(12):51. https://doi.org/10.1186/s12974-015-0270-3
doi: 10.1186/s12974-015-0270-3
Wang H-W, Jiang X, Zhang Y et al (2019) FGF21 protects against hypoxia injury through inducing HSP72 in cerebral microvascular endothelial cells. Front Pharmacol 10. https://doi.org/10.3389/fphar.2019.00101
Xiong T, Tang J, Zhao J et al (2012) Involvement of the Akt/GSK-3β/CRMP-2 pathway in axonal injury after hypoxic–ischemic brain damage in neonatal rat. Neuroscience 216:123–132. https://doi.org/10.1016/j.neuroscience.2012.04.052
doi: 10.1016/j.neuroscience.2012.04.052
pubmed: 22554777
Zhang W, Liu J, Hu X et al (2015) n -3 Polyunsaturated fatty acids reduce neonatal hypoxic/ischemic brain injury by promoting phosphatidylserine formation and akt signaling. Stroke 46:2943–2950. https://doi.org/10.1161/strokeaha.115.010815
doi: 10.1161/strokeaha.115.010815
pubmed: 26374481
Pan Y, Wang B, Zheng J et al (2018) Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. J Cell Mol Med 23:1059–1071. https://doi.org/10.1111/jcmm.14007
doi: 10.1111/jcmm.14007
pubmed: 30461198
pmcid: 6349243
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. https://doi.org/10.1038/nature05292
doi: 10.1038/nature05292
pubmed: 17051205
Ballatore C, Lee VM-Y, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672. https://doi.org/10.1038/nrn2194
doi: 10.1038/nrn2194
pubmed: 17684513
Grundke-Iqbal I, Iqbal K, Tung Y-C et al (1987) Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology. Alzheimer Dis Assoc Disord 1:202. https://doi.org/10.1097/00002093-198701030-00020
doi: 10.1097/00002093-198701030-00020
Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312–339. https://doi.org/10.1016/j.cell.2019.09.001
doi: 10.1016/j.cell.2019.09.001
pubmed: 31564456
pmcid: 6778042
Bélanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14:724–738. https://doi.org/10.1016/j.cmet.2011.08.016
doi: 10.1016/j.cmet.2011.08.016
pubmed: 22152301
Garden GA, La Spada AR (2012) Intercellular (mis)communication in neurodegenerative disease. Neuron 73:886–901. https://doi.org/10.1016/j.neuron.2012.02.017
doi: 10.1016/j.neuron.2012.02.017
pubmed: 22405200
pmcid: 3334539
Escartin C, Valette J, Lebon V, Bonvento G (2006) Neuron?astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy. J Neurochem 99:393–401. https://doi.org/10.1111/j.1471-4159.2006.04083.x
doi: 10.1111/j.1471-4159.2006.04083.x
pubmed: 17029594
Sun Y, Wang Y, Chen S-T et al (2020) Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21. Theranostics 10:8430–8445. https://doi.org/10.7150/thno.44370
doi: 10.7150/thno.44370
pubmed: 32724479
pmcid: 7381735
Sa-nguanmoo P, Tanajak P, Kerdphoo S et al (2018) FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. Biomed Pharmacother 97:1663–1672. https://doi.org/10.1016/j.biopha.2017.12.021
doi: 10.1016/j.biopha.2017.12.021
pubmed: 29793329
Sa-nguanmoo P, Tanajak P, Kerdphoo S et al (2016) FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm Behav 85:86–95. https://doi.org/10.1016/j.yhbeh.2016.08.006
doi: 10.1016/j.yhbeh.2016.08.006
pubmed: 27566237
Mäkelä J, Tselykh TV, Maiorana F et al (2014) Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1. SpringerPlus 3:2. https://doi.org/10.1186/2193-1801-3-2
doi: 10.1186/2193-1801-3-2
pubmed: 25932355
pmcid: 4409609
Yang C, Wang W, Deng P et al (2021) Fibroblast growth factor 21 modulates microglial polarization that attenuates neurodegeneration in mice and cellular models of Parkinson’s disease. Front Aging Neurosci 13. https://doi.org/10.3389/fnagi.2021.778527
Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029
doi: 10.1038/nature21029
pubmed: 28099414
pmcid: 5404890
Qin Y, Qiu J, Wang P et al (2021) Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson’s disease. Brain Behav Immun 91:324–338. https://doi.org/10.1016/j.bbi.2020.10.010
doi: 10.1016/j.bbi.2020.10.010
pubmed: 33039664
Wang Q, Yuan J, Yu Z et al (2017) FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. Mol Neurobiol 55:4702–4717. https://doi.org/10.1007/s12035-017-0663-7
doi: 10.1007/s12035-017-0663-7
pubmed: 28712011
pmcid: 5971086
Campderrós L, Moure R, Cairó M et al (2019) Brown adipocytes secrete GDF15 in response to thermogenic activation. Obesity 27:1606–1616. https://doi.org/10.1002/oby.22584
doi: 10.1002/oby.22584
pubmed: 31411815
Strelau J, Sullivan A, Böttner M et al (2000) Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 20:8597–8603. https://doi.org/10.1523/jneurosci.20-23-08597.2000
doi: 10.1523/jneurosci.20-23-08597.2000
pubmed: 11102463
pmcid: 6773071
Schober A, Böttner M, Strelau J et al (2001) Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 439:32–45. https://doi.org/10.1002/cne.1333
doi: 10.1002/cne.1333
pubmed: 11579380
Fuchs T, Trollor JN, Crawford J et al (2013) Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney memory and aging study. Aging Cell 12:882–889. https://doi.org/10.1111/acel.12116
doi: 10.1111/acel.12116
pubmed: 23758647
Mu Y, Gage FH (2011) Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 6:85. https://doi.org/10.1186/1750-1326-6-85
doi: 10.1186/1750-1326-6-85
pubmed: 22192775
pmcid: 3261815
Emmerson PJ, Wang F, Du Y et al (2017) The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 23:1215–1219. https://doi.org/10.1038/nm.4393
doi: 10.1038/nm.4393
pubmed: 28846098
Yang L, Chang C-C, Sun Z et al (2017) GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23:1158–1166. https://doi.org/10.1038/nm.4394
doi: 10.1038/nm.4394
pubmed: 28846099
Li Z, Wang B, Wu X et al (2005) Identification, expression and functional characterization of the GRAL gene. J Neurochem 95:361–376. https://doi.org/10.1111/j.1471-4159.2005.03372.x
doi: 10.1111/j.1471-4159.2005.03372.x
pubmed: 16086688
Tan M, Wang Y, Guan K, Sun Y (2000) PTGF-β , a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci USA 97:109–114. https://doi.org/10.1073/pnas.97.1.109
doi: 10.1073/pnas.97.1.109
pubmed: 10618379
pmcid: 26624
Pagel J-I, Deindl E (2012) Disease progression mediated by Egr-1 associated signaling in response to oxidative stress. IJMS 13:13104–13117. https://doi.org/10.3390/ijms131013104
doi: 10.3390/ijms131013104
pubmed: 23202940
pmcid: 3497314
Kadowaki M, Yoshioka H, Kamitani H et al (2011) DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer 130:267–277. https://doi.org/10.1002/ijc.26082
doi: 10.1002/ijc.26082
pubmed: 21437897
pmcid: 3133861
Woo SM, Min K, Kim S et al (2014) Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation. Chem-Biol Interact 211:36–43. https://doi.org/10.1016/j.cbi.2014.01.004
doi: 10.1016/j.cbi.2014.01.004
pubmed: 24440808
Yamaguchi H, Nishiyama M, Tokumoto S et al (2021) Elevated cytokine, chemokine, and growth and differentiation factor-15 levels in hemorrhagic shock and encephalopathy syndrome: a retrospective observational study. Cytokine 137:155324. https://doi.org/10.1016/j.cyto.2020.155324
doi: 10.1016/j.cyto.2020.155324
pubmed: 33032108
Zhu S, Yang N, Guan Y et al (2021) GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2–c-Fos–LIF signaling. Cell Death Discov 7. https://doi.org/10.1038/s41420-020-00395-8
Conte M, Martucci M, Chiariello A et al (2020) Mitochondria, immunosenescence and inflammaging: a role for mitokines? Semin Immunopathol 42:607–617. https://doi.org/10.1007/s00281-020-00813-0
doi: 10.1007/s00281-020-00813-0
pubmed: 32757036
pmcid: 7666292
Rochette L, Zeller M, Cottin Y, Vergely C (2020) Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab 31:939–951. https://doi.org/10.1016/j.tem.2020.10.004
doi: 10.1016/j.tem.2020.10.004
pubmed: 33172749
Jin Y-J, Lee J-H, Kim Y-M et al (2012) Macrophage inhibitory cytokine-1 stimulates proliferation of human umbilical vein endothelial cells by up-regulating cyclins D1 and E through the PI3K/Akt-, ERK-, and JNK-dependent AP-1 and E2F activation signaling pathways. Cell Signal 24:1485–1495. https://doi.org/10.1016/j.cellsig.2012.03.014
doi: 10.1016/j.cellsig.2012.03.014
pubmed: 22484283
Schindowski K, von Bohlen und Halbach O, Strelau J et al (2010) Regulation of GDF-15, a distant TGF-β superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res 343:399–409. https://doi.org/10.1007/s00441-010-1090-5
doi: 10.1007/s00441-010-1090-5
pubmed: 21128084
pmcid: 3032194
Song H, Yin D, Liu Z (2011) GDF-15 promotes angiogenesis through modulating p53/HIF-1α signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 39:4017–4022. https://doi.org/10.1007/s11033-011-1182-7
doi: 10.1007/s11033-011-1182-7
pubmed: 21773947
Park H, Nam K-S, Lee H-J, Kim KS (2022) Ionizing radiation-induced GDF15 promotes angiogenesis in human glioblastoma models by promoting VEGFA expression through p-MAPK1/SP1 signaling. Front Oncol 12. https://doi.org/10.3389/fonc.2022.801230
Li M, Song K, Huang X et al (2018) GDF-15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice. Int J Mol Med. https://doi.org/10.3892/ijmm.2018.3747
Yuan L, Li S, Chen Q et al (2022) EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ 29:1513–1527. https://doi.org/10.1038/s41418-022-00939-8
doi: 10.1038/s41418-022-00939-8
pubmed: 35105963
pmcid: 9346003
Hou K, Shen J, Yan J et al (2021) Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine 69:103456. https://doi.org/10.1016/j.ebiom.2021.103456
doi: 10.1016/j.ebiom.2021.103456
pubmed: 34233258
pmcid: 8261003
Xia M, Zhang Q, Zhang Y et al (2022) Growth differentiation factor 15 regulates oxidative stress-dependent ferroptosis post spinal cord injury by stabilizing the p62-Keap1-Nrf2 signaling pathway. Front Aging Neurosci 14. https://doi.org/10.3389/fnagi.2022.905115
Zhang Y, Khan S, Liu Y et al (2022) Modes of brain cell death following intracerebral hemorrhage. Front Cell Neurosci 16. https://doi.org/10.3389/fncel.2022.799753
Chen J, Peng H, Chen C et al (2022) NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. Life Sci 311:121142. https://doi.org/10.1016/j.lfs.2022.121142
doi: 10.1016/j.lfs.2022.121142
pubmed: 36367498
Brenière C, Méloux A, Pédard M et al (2019) Growth differentiation factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. Front Neurol 10. https://doi.org/10.3389/fneur.2019.00611
Zang Y, Zhu Z, Xie Y et al (2022) Serum growth differentiation factor 15 levels are associated with depression after ischemic stroke. JAHA 11. https://doi.org/10.1161/jaha.121.022607
Worth AA, Shoop R, Tye K et al (2020) The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling. eLife 9. https://doi.org/10.7554/elife.55164
Cimino I, Kim H, Tung YCL et al (2021) Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15. Proc Natl Acad Sci USA 118. https://doi.org/10.1073/pnas.2106868118
Liu D-D, Lu J-M, Zhao Q-R et al (2016) Growth differentiation factor-15 promotes glutamate release in medial prefrontal cortex of mice through upregulation of T-type calcium channels. Sci Rep 6. https://doi.org/10.1038/srep28653
Wang Y, Zhen C, Wang R, Wang G (2019) Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: a meta-analysis. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2019.04.035
Xiong W-P, Yao W-Q, Wang B, Liu K (2021) BMSCs-exosomes containing GDF-15 alleviated SH-SY5Y cell injury model of Alzheimer’s disease via AKT/GSK-3β/β-catenin. Brain Res Bull 177:92–102. https://doi.org/10.1016/j.brainresbull.2021.09.008
doi: 10.1016/j.brainresbull.2021.09.008
pubmed: 34536520
Park B-N, Kim J-H, Lim TS et al (2020) Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer’s disease evaluated by β-amyloid positron emission tomography imaging. Aust N Z J Psychiatry 54:883–891. https://doi.org/10.1177/0004867420917467
doi: 10.1177/0004867420917467
pubmed: 32436738
Maetzler W, Deleersnijder W, Hanssens V et al (2016) GDF15/MIC1 and MMP9 Cerebrospinal fluid levels in Parkinson’s disease and lewy body dementia. PLoS One 11:e0149349. https://doi.org/10.1371/journal.pone.0149349
doi: 10.1371/journal.pone.0149349
pubmed: 26938614
pmcid: 4777571
Machado V, Haas SJ-P, von Bohlen und Halbach O et al (2016) Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neurobiol Dis 88:1–15. https://doi.org/10.1016/j.nbd.2015.12.016
doi: 10.1016/j.nbd.2015.12.016
pubmed: 26733415
Machado V, Gilsbach R, Das R et al (2016) Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice. Cell Tissue Res 365:209–223. https://doi.org/10.1007/s00441-016-2406-x
doi: 10.1007/s00441-016-2406-x
pubmed: 27115420
Obeso JA, Rodriguez-Oroz MC, Goetz CG et al (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16:653–661. https://doi.org/10.1038/nm.2165
doi: 10.1038/nm.2165
pubmed: 20495568
Ruth M (2012) A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis. Yearbook of Endocrinol 2012:114–116. https://doi.org/10.1016/j.yend.2012.04.012
doi: 10.1016/j.yend.2012.04.012
Yu Q, Kou W, Xu X et al (2019) FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci 133:611–627. https://doi.org/10.1042/cs20190016
doi: 10.1042/cs20190016
Tanhaei S, Nikpour P, Ghaedi K et al (2018) RNA/protein discordant expression of Fndc5 in central nervous system is likely to be mediated through microRNAs. DNA Cell Biol 37:373–380. https://doi.org/10.1089/dna.2017.4067
doi: 10.1089/dna.2017.4067
pubmed: 29461897
Wrann CD, White JP, Salogiannnis J et al (2013) Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab 18:649–659. https://doi.org/10.1016/j.cmet.2013.09.008
doi: 10.1016/j.cmet.2013.09.008
pubmed: 24120943
pmcid: 3980968
Torma F, Bori Z, Koltai E et al (2014) Eating habits modulate short term memory and epigenetical regulation of brain derived neurotrophic factor in hippocampus of low- and high running capacity rats. Brain Res Bull 107:54–60. https://doi.org/10.1016/j.brainresbull.2014.07.003
doi: 10.1016/j.brainresbull.2014.07.003
pubmed: 25043449
Siteneski A, Olescowicz G, Pazini FL et al (2020) Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDC5/irisin pathway. J Neural Transm 127:355–370. https://doi.org/10.1007/s00702-020-02143-9
doi: 10.1007/s00702-020-02143-9
pubmed: 31974720
Qin L, Bouchard R, Pugazhenthi S (2016) Regulation of cyclic AMP response element-binding protein during neuroglial interactions. J Neurochem 136:918–930. https://doi.org/10.1111/jnc.13497
doi: 10.1111/jnc.13497
pubmed: 26677139
Lourenco MV, Ribeiro FC, Sudo FK, et al (2020) Cerebrospinal fluid irisin correlates with amyloid-β, BDNF, and cognition in Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 12. https://doi.org/10.1002/dad2.12034
Islam MR, Valaris S, Young MF et al (2021) Exercise hormone irisin is a critical regulator of cognitive function. Nat Metab 3:1058–1070. https://doi.org/10.1038/s42255-021-00438-z
doi: 10.1038/s42255-021-00438-z
pubmed: 34417591
pmcid: 10317538
Jodeiri Farshbaf M, Alviña K (2021) Multiple roles in neuroprotection for the exercise derived myokine irisin. Front Aging Neurosci 13. https://doi.org/10.3389/fnagi.2021.649929
Rabiee F, Lachinani L, Ghaedi S et al (2020) New insights into the cellular activities of Fndc5/Irisin and its signaling pathways. Cell Biosci 10. https://doi.org/10.1186/s13578-020-00413-3
Guo P, Liu L, Yang X et al (2022) Irisin improves BBB dysfunction in SAP rats by inhibiting MMP-9 via the ERK/NF-κB signaling pathway. Cell Signal 93:110300. https://doi.org/10.1016/j.cellsig.2022.110300
doi: 10.1016/j.cellsig.2022.110300
pubmed: 35259454
Zhao R (2022) Irisin at the crossroads of inter-organ communications: challenge and implications. Front Endocrinol 13. https://doi.org/10.3389/fendo.2022.989135
Ahmadi Ghahrizjani F, Ghaedi K, Salamian A et al (2015) Enhanced expression of FNDC5 in human embryonic stem cell-derived neural cells along with relevant embryonic neural tissues. Gene 557:123–129. https://doi.org/10.1016/j.gene.2014.12.010
doi: 10.1016/j.gene.2014.12.010
Wang Y, Xu E, Musich PR, Lin F (2019) Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure. CNS Neurosci Ther 25:816–824. https://doi.org/10.1111/cns.13116
doi: 10.1111/cns.13116
pubmed: 30889315
pmcid: 6566063
Mani S, Swargiary G, Chadha R (2021) Mitophagy impairment in neurodegenerative diseases: pathogenesis and therapeutic interventions. Mitochondrion 57:270–293. https://doi.org/10.1016/j.mito.2021.01.001
doi: 10.1016/j.mito.2021.01.001
pubmed: 33476770
Norris GT, Kipnis J (2018) Immune cells and CNS physiology: microglia and beyond. J Exp Med 216:60–70. https://doi.org/10.1084/jem.20180199
doi: 10.1084/jem.20180199
pubmed: 30504438
Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res 2018:1–12. https://doi.org/10.1155/2018/4784268
doi: 10.1155/2018/4784268
Qi J, Yang L, Wang X et al (2022) Irisin: a promising treatment for neurodegenerative diseases. Neuroscience 498:289–299. https://doi.org/10.1016/j.neuroscience.2022.07.018
doi: 10.1016/j.neuroscience.2022.07.018
pubmed: 35872251
Lourenco MV, de Freitas GB, Raony Í et al (2022) Irisin stimulates protective signaling pathways in rat hippocampal neurons. Front Cell Neurosci 16. https://doi.org/10.3389/fncel.2022.953991
Lourenco MV, Arancio O, Ferreira ST, De Felice FG (2019) P2-162: Exercise-linked FNDC5/Irisin corrects synaptic plasticity and memory defects in mouse models of Alzheimer’s disease. Alzheimer’s & Dementia 15:P637–P638. https://doi.org/10.1016/j.jalz.2019.06.2569
doi: 10.1016/j.jalz.2019.06.2569
Noda Y, Kuzuya A, Tanigawa K et al (2018) Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease. Mol Brain 11. https://doi.org/10.1186/s13041-018-0401-8
Tu W-J, Qiu H-C, Cao J-L et al (2018) Decreased concentration of irisin is associated with poor functional outcome in ischemic stroke. Neurotherapeutics 15:1158–1167. https://doi.org/10.1007/s13311-018-0651-2
doi: 10.1007/s13311-018-0651-2
pubmed: 30030698
pmcid: 6277286
Tu T, Peng J, Jiang Y (2020) FNDC5/Irisin: a new protagonist in acute brain injury. Stem Cells Dev 29:533–543. https://doi.org/10.1089/scd.2019.0232
doi: 10.1089/scd.2019.0232
pubmed: 31914844
Øverberg LT, Lugg EF, Gaarder M et al (2022) Plasma levels of BDNF and EGF are reduced in acute stroke patients. Heliyon 8:e09661. https://doi.org/10.1016/j.heliyon.2022.e09661
doi: 10.1016/j.heliyon.2022.e09661
pubmed: 35756121
pmcid: 9218156
Xu X, Zhou R, Ying J et al (2023) Irisin prevents hypoxic-ischemic brain damage in rats by inhibiting oxidative stress and protecting the blood-brain barrier. Peptides 161:170945. https://doi.org/10.1016/j.peptides.2023.170945
doi: 10.1016/j.peptides.2023.170945
pubmed: 36623553
Jin Z, Zhang Z, Ke J et al (2021) Exercise-linked irisin prevents mortality and enhances cognition in a mice model of cerebral ischemia by regulating klotho expression. Oxid Med Cell Longevity 2021:1–16. https://doi.org/10.1155/2021/1697070
doi: 10.1155/2021/1697070
Jin Z, Guo P, Li X et al (2019) Neuroprotective effects of irisin against cerebral ischemia/reperfusion injury via Notch signaling pathway. Biomed Pharmacother 120:109452. https://doi.org/10.1016/j.biopha.2019.109452
doi: 10.1016/j.biopha.2019.109452
pubmed: 31561067
Zhu D, Wang H, Zhang J et al (2015) Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol 87:138–147. https://doi.org/10.1016/j.yjmcc.2015.07.015
doi: 10.1016/j.yjmcc.2015.07.015
pubmed: 26225842
Lu J, Xiang G, Liu M et al (2015) Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis 243:438–448. https://doi.org/10.1016/j.atherosclerosis.2015.10.020
doi: 10.1016/j.atherosclerosis.2015.10.020
pubmed: 26520898
Wang Y, Tian M, Tan J et al (2022) Irisin ameliorates neuroinflammation and neuronal apoptosis through integrin αVβ5/AMPK signaling pathway after intracerebral hemorrhage in mice. J Neuroinflammation 19. https://doi.org/10.1186/s12974-022-02438-6
Peng J, Deng X, Huang W et al (2017) Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway. Mol Immunol 91:185–194. https://doi.org/10.1016/j.molimm.2017.09.014
doi: 10.1016/j.molimm.2017.09.014
pubmed: 28961497
Yu Q, Li G, Ding Q et al (2020) Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway. Cerebrovasc Dis 49:346–354. https://doi.org/10.1159/000505961
doi: 10.1159/000505961
pubmed: 32756048